Cytotoxic action of phorbol esters on human pancreatic cancer cells

International Journal of Cancer

Volumn 121, Issue 7, 2007, Pages 1445-1454

  Bond, Jane A ^a   Gescher, Andreas J ^b   Verschoyle, Richard D ^b   Lemoine, Nicholas R ^c   Errington, Rachel ^a   Wiltshire, Marie ^a   Smith, Paul J ^a   Wynford Thomas, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Cell death; Pancreas; Phorbol ester; Therapy

Indexed keywords

BRYOSTATIN 1; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL DIBUTYRATE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL DEATH; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALEIMIDES; MEMBRANE PROTEINS; MICE; PANCREATIC NEOPLASMS; PHORBOL 12,13-DIBUTYRATE; PHORBOL ESTERS; PHOSPHORYLATION; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548254451     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22869     Document Type: Article

References (48)

1. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
3. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
4. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4:159-64.
5. Schutte M, Kern SE. The molecular genetics of pancreatic adenocarcinoma. In: Neoptolemos JP, Lemoine NR. eds. Pancreatic cancer. Oxford: Black well Scientific Publications, 1996;115-32.
6. Wynford-Thomas D. Molecular genetics of thyroid cancer. Curr Opin Endocrinol Diab 1995;2:429-36.
7. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 1994;9:281-90.
8. Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford-Thomas D, Bond JA. Evidence for a telomere-independent "clock"; limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol Cell Biol 2000;20:5690-99.
9. Blumberg M. Complexities of the protein kinase C pathway. Mol Carcinogen 1991;4:339-44.
10. Bond J, Dawson T, Lemoine NR, Wynford-Thomas D. Effect of serum growth factors and phorbol ester on growth and survival of human thyroid epithelial cells expressing mutant ras. Mol Carcinogen 1992;5:129-35.
11. Dawson T, Bond J, Eccles N, Wynford-Thomas D. Toxicity of phorbol esters for human epithelial ceils expressing a mutant ras oncogene. Mol Carcinogen 1993;8:280-9.
12. Hall-Jackson C, Jones T, Eccles N, Dawson T, Bond J, Gescher A, Wynford-Thomas D. Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target. Br J Cancer 1998;78:641-51.
13. Parker PJ, Bosca L, Dekker L, Goode NT, Hajibagheri N, Hansra G. Protein kinase C (PKC)-induced PKC degradation: a model for down-regulation. Biochem Soc Trans 1995;23:153-5.
14. Droms KA, Malkinson AM. Phorbol ester-induced tumor promotion by downregulation of protein kinase C. Mol Carcinogen 1991;4:1-2.
15. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72.
16. Thorpe WP, Toner M, Ezzell RM, Tompkins RG, Yarmush ML. Dynamics of photoinduced cell plasma membrane injury. Biophys J 1995;68:2198-206.
17. Smith PJ, Blunt N, Wiltshire M, Hoy T, Teesdale-Spittle P, Craven MR, Watson JV, Amos WB, Errington RJ, Patterson LH. Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopy. Cytometry 2000;40:280-91.
18. Bond J, Haughton M, Rowson J, Gtre V, Wynford-Thomas D, Wyllie F. Control of replicattve lifespan in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol 1999;19:3103-14.
19. Marshman E, Ottewell PD, Potten CS, Watson AJ. Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol 2001;195:285-92.
20. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001;439:798-802.
21. Sirivatanauksorn V, Sirivatanauksom Y, Gorman PA, Davidson JM, Sheer D, Moore PS, Scarpa A, Edwards PAW, Lemoine NR. Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. Int J Cancer 2001;91:350-8.
22. Wang QJ, Fang TW, Fenick D, Fenick D, Garfield S, Bienfait B, Marquez VE, Blumberg PM. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J Biol Chem 2000;275:12136-46.
23. Stone RM, Sariban E, Pettit GR, Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988;72:208-13.
24. Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL. A phase 11 study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 1998;78:1337-41.
25. Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriquez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000;6:825-8.
26. Stanwell C, Gescher A, Bradshaw TD, Pettit GR. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer 1994;56:585-92.
27. Graff JM, Young TN, Johnson JD, Blackshear PJ. Phosphorylation-regulated calmodulin binding to a prominent substrate for protein kinase C. J Biol Chem 1989;264:21818-23.
28. Barry OP, Kazanietz MG. Protein kinase c isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 2001;7:1725-44.
29. Day ML, Zhao X, Wu S, Swanson PE, Humphrey PA. Phorbol esterinduced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ 1994;5:735-41.
30. Zheng X, Chang RL, Cui X-X, Avila GE, Lee S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson AB, et al. Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumours in immunodeficient mice. Cancer Res 2004;64:1811-20.
31. Park IC, Park MJ, Rhee CH, Lee JI, Choe TB, Jang JJ, Lee SH, Hong SI. Protein kinase C activation by PMA rapidly induces apoptosis through caspase-3/CPP32 and serine protease(s) in a gastric cancer cell line. Int J Oncol 2001;18:1077-83.
32. Avila GE, Zheng X, Cui XX, Ryan AD, Hansson A, Suh J, Rabson AB, Chang RL, Shih WJ, Lin Y, Crowell P, Lu YP, et al. Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice. J Pharmacol Exp Ther 2005;315:170-87.
33. Powell CT, Yin L. Overexpression of PKCΣ sensitizes LNCaP human prostate cells to induction of apoptosis by bryostatin 1. Int J Cancer 2006;118:1572-6.
34. Engedal N, Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 2001;46:289-97.
35. Detjen KM, Brembeck FH, Welzel M, Kaiser A, Haller H, Weidenmann B, Rosewicz S. Activation of protein kinase C alpha inhibits growth of pancreatic cancer cells via p 21(cip)-mediated G1 arrest. J Cell Sci 2000;113:3025-35.
36. Kazanietz MG, Caloca MJ, Eroles P, Fujii T, Garcia-Bermejo ML, Reilly M, Wang H. Pharmacology of the receptors for the phorbol ester tumor promoters: multiple receptors with different biochemical properties. Biochem Pharmacol 2000;60:1417-24.
37. Kazanietz MG. Targeting protein kinase C and "non-kinase" phorbol ester receptors: emerging concepts and therapeutic implications. Biochim Biophys Acta 2005;1754:296-304.
38. Tognon CE, Kirk HE, Passmore LA, Whitehead IP, Der CJ, Kay RJ. Regulation of Ras GRP via a phorbol ester-responsive Cl domain. Mol Cell Biol 1998;18:6995-7008.
39. Caloca MJ, Fernandez N, Lewin NE, Ching D, Modali R, Blumberg PM, Kazanietz MG. Beta 2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters. J Biol Chem 1997;272:26488-96.
40. Brose N, Rosenmund C. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. J Cell Sci 2002;115:4399-411.
41. Song Y, Ailenberg M, Silverman M. Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Mol Biol Cell 1999;10:1609-19.
42. Hamada K, Nakamura H, Oda T, Hirano T, Shimizu N, Utiyama H. Involvement of Mac-1-mediated adherence and sphingosine 1-phosphate in survival of phorbol ester-treated U937 cells. Biochem Biophys Res Commun 1998;244:745-50.
43. Rosfjord EC, Maemura M, Johnson MD, Torri JA, Akiyama SK, Woods VL, Jr, Dickson RB. Activation of protein kinase C by phorbol esters modulates alpha 2beta 1 integrin on MCF-7 breast cancer cells. Exp Cell Res 1999;248:260-71.
44. Strair RK, Schaar D, Goodell L, Aisner J, Chin KV, Eid J, Senzan R, Cui XX, Han ZT, Knox B, Rabson AB, Chang R, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002;8:2512-18.
45. Han ZT, Tong YK, He LM, Zhang Y, Sun JZ, Wang TY, Zhang H, Cui YL, Newmark HL, Conney AH, Chang RL. 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad of Sci USA 1998a;95:5362-5.
46. Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu XJ, Cao GS, Newmark HL, Conney AH, Chang RL. Effect of intravenous infusions of 12- O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad of Sci USA 1998b;95:5357-61.
47. Cui XX, Chang RL, Zheng X, Woodward D, Strair R, Conney AH. A sensitive bioassay for measuring blood levels of 12-O-Tetradecanoylphorbol-13- acetate(TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 2002;13:169-74.
48. Schaar D, Goodell L, Aisner J, Cui XX, Han ZT, Chang R, Martin J, Grospe S, Dudek L, Riley J, Manago J, Lin Y, et al. A phase 1 clinical trial of 12 O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol 2006;57:789-95.